These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20933338)
21. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
22. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Testa CM; Sherer TB; Greenamyre JT Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535 [TBL] [Abstract][Full Text] [Related]
23. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932 [TBL] [Abstract][Full Text] [Related]
24. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040 [TBL] [Abstract][Full Text] [Related]
25. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. McRitchie DA; Cartwright HR; Halliday GM Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172 [TBL] [Abstract][Full Text] [Related]
26. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435 [TBL] [Abstract][Full Text] [Related]
27. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Locke CJ; Fox SA; Caldwell GA; Caldwell KA Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411 [TBL] [Abstract][Full Text] [Related]
28. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Rojo AI; Cavada C; de Sagarra MR; Cuadrado A Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941 [TBL] [Abstract][Full Text] [Related]
29. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399 [TBL] [Abstract][Full Text] [Related]
30. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
32. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). Schmidt WJ; Alam M J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541 [TBL] [Abstract][Full Text] [Related]
33. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446 [TBL] [Abstract][Full Text] [Related]
34. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674 [TBL] [Abstract][Full Text] [Related]
35. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism. Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469 [TBL] [Abstract][Full Text] [Related]
36. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease. Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343 [TBL] [Abstract][Full Text] [Related]
37. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins. Nagel F; Bähr M; Dietz GP Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215 [TBL] [Abstract][Full Text] [Related]
38. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Sulzer D Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429 [TBL] [Abstract][Full Text] [Related]
39. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons. Mocchetti I; Bachis A; Nosheny RL; Tanda G Neurotox Res; 2007 Sep; 12(2):135-43. PubMed ID: 17967737 [TBL] [Abstract][Full Text] [Related]
40. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Li LH; Qin HZ; Wang JL; Wang J; Wang XL; Gao GD J Int Med Res; 2009; 37(2):455-63. PubMed ID: 19383240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]